BRM423

BRM423 is a novel synthetic peptide drug candidate developed by BRIM Biotechnology. It is derived from human Pigment Epithelium-Derived Factor (PEDF) and belongs to the class of PEDF-derived short peptides (PDSP). The active ingredient in BRM423 is the same as that in BRM421, but it is specifically targeted for the treatment of severe corneal damage, including conditions such as corneal burns, ulcers, abrasions, and to accelerate post-surgical wound healing. The mechanism of action involves stimulating limbal stem cell proliferation and differentiation to promote rapid corneal wound healing and repair. Preclinical studies have shown that PDSPs like BRM423 can expand limbal stem cells (LSCs), maintain their ability to differentiate into corneal cells, support self-renewal, and significantly accelerate re-epithelialization of the cornea. The drug also exhibits neurotrophic properties with potential anti-inflammatory effects that may improve tear quality through goblet cell growth. As of early 2025, its highest clinical development phase is Phase 1 for severe corneal injuries[1][2][3][4][5].